- DocAiPharmacy Editorial Team
- Guías de bienestar
Educational Disclaimer: This article is for general educational purposes only and does not provide personalized medical advice. Readers should always read product labels carefully and consult a pharmacist or licensed health care professional for any questions about dosing or storage.
Over‑the‑counter (OTC) medications carry Drug Facts labels designed to guide consumers safely. However, research and regulatory guidance show that label misinterpretations—especially concerning dosing intervals and storage—remain common, particularly among individuals with limited health literacy. User‑testing studies have been invaluable in identifying these issues and informing improvements.
User Testing Reveals Common Misinterpretations
A study testing five OTC diclofenac labels with 50 consumers asked when they would take the drug for constant back pain starting at 8 a.m. and where they’d store it. Only 29 respondents chose an appropriate dosing interval (e.g., every 8 hours), while 19 proposed shorter, riskier intervals driven by factors like desire for prompt pain relief or fitting a full 24‑hour dosing schedule. Storage responses were also problematic: only 29 described suitable storage locations (such as a medicine cabinet), while others suggested less ideal spots. These findings underscore how even straightforward wording can be misinterpreted under real‑world considerations. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1551741116301024?utm_source=openai))
Why Misinterpretations Happen
A systematic review of drug label textual elements found that multi‑step instructions, medical jargon, and abbreviations hinder comprehension. Clear text, explicit timing, plain language, and numeric formats in users’ native languages facilitate better understanding. For example, “Take one tablet every morning, one every evening” is more understandable than “Take one tablet twice daily.” ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133485/?utm_source=openai))
Research on auxiliary illustrations suggests they may not reliably improve comprehension. In one study, illustrations improved performance for some but worsened it for others—especially when users focused on the image at the expense of the text. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1177941/?utm_source=openai))
Regulatory Guidance Supports Iterative Testing
The U.S. Food and Drug Administration (FDA) recommends that sponsors conduct label comprehension studies before finalizing nonprescription drug labels. Such studies should assess whether consumers, including those with lower literacy, can read and apply dosing, storage, warnings, and other information. This guidance supports iterative label design. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/label-comprehension-studies-nonprescription-drug-products?utm_source=openai))
Health Canada similarly requires consumer use studies—including label comprehension, self‑selection, and actual use studies—for nonprescription switches. These studies must involve participants with varying literacy and demographics and be close to the final label version. ([canada.ca](https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/switching-prescription-non-prescription-status/consumer-use-studies.html?utm_source=openai))
Performance‑based user testing, such as that used for the FDA’s OTC naloxone label, measures whether label users can identify key actions, such as recognizing overdose and calling emergency services. Testing must include real‑world scenarios, low‑literacy users, and time pressure to ensure safety messages are understood in critical contexts. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC13704687/?utm_source=openai))
Principles for Better OTC Labels
- Use plain, explicit language: avoid Latin abbreviations and jargon.
- Present each instruction step separately and clearly.
- Use numeric dosage (e.g., “2 tablets”) rather than spelled‑out numbers when possible.
- State timing clearly (“in the morning” vs. “twice daily”).
- Use users’ native language when feasible to reduce misinterpretation.
- Test with diverse users—including low‑literacy and older adults—under realistic conditions.
When Overdose or Misuse Occurs
If users accidentally take too much of an OTC medication—or are unsure—seek help immediately. In the U.S., call the Poison Help Line at 1‑800‑222‑1222. This service is available 24/7 to provide expert guidance. Do not wait to see if symptoms develop. When in doubt, seek professional evaluation promptly.
Role of Pharmacists at DocAiPharmacy
At DocAiPharmacy, pharmacists play a critical role in bridging the gap between label information and safe consumer use. You can:
- Clarify dosing intervals and maximum per‑day limits.
- Demonstrate the use of measuring tools for liquid doses (e.g., dosing cups, syringes).
- Advise on proper storage (cool, dry place, out of children’s reach, per product instructions).
- Encourage users to read labels each time—since formulations and strengths may change.
- Emphasize critical information such as warnings, contraindications, and when to consult a physician.
By combining regulatory best practices, user‑testing evidence, and pharmacist counseling, we can reduce common label misunderstandings—supporting safer, more effective self‑care with OTC medicines.
Pharmacist Consultation Guidance: Always encourage customers to ask questions when uncertain about label directions. Offer verbal and written reinforcement during the visit. When appropriate, recommend contacting a health care provider, especially if symptoms persist or dosing uncertainty remains.
Official sources
- The impact of textual elements on the comprehensibility of drug label instructions (DLIs): A systematic review
- Label Comprehension Studies for Nonprescription Drug Products (FDA guidance)
- Performance‑Based User Testing and Nonprescription Labels (systematic review)
- The Over‑the‑Counter Drug Facts Label (FDA)